Journal article

Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis

Stephanie Grabow, Alex RD Delbridge, Brandon J Aubrey, Cassandra J Vandenberg, Andreas Strasser

Cell Reports | CELL PRESS | Published : 2016


Awarded by National Health and Medical Research Council

Awarded by Leukemia and Lymphoma Society (SCOR grant)

Funding Acknowledgements

We thank Dr. J.M. Adams for comments on the manuscript; Drs. P.M. Colman, G.L. Kelly, and L.A. O'Reilly for stimulating discussions and support; Drs. P. Bouillet, S. Cory, A. Villunger, and T. Jacks for mouse strains; Drs. S. Wilcox and A. Kueh for DNA sequence analysis; J. Mansheim, S. O'Connor, K. Walker, C. Gatt, S. Allan, T. Bertenis, C. D'Alessandro, and G. Siciliano for animal care; J. Corbin and J. McManus for automated blood analysis; B. Helbert for mouse genotyping; and E. Tsui, V. Babo, K. Weston, Y. Hoang, C. Tsui, and S. Hasanein for histology. Our research was supported by grants and fellowships from the Cancer Council of Victoria (postdoctoral fellowship to S.G. and A.R.D.D.), the Lady Tata Memorial Trust (postdoctoral research award to S.G.), Leukaemia Foundation Australia (postdoctoral fellowship to S.G.), the National Health and Medical Research Council (program grant 1016701; NHMRC fellowship 1020363, all to A. S.), the Leukemia and Lymphoma Society (SCOR grant 7001-03 to A. S.), the estate of Anthony (Toni) Redstone OAM, University of Melbourne International Research and International Fee Remission Scholarships (S.G.), Australian Postgraduate Award (A.R.D.D.), Leukaemia Foundation National Research Program Clinical PhD Scholarship (B.J.A.), Cancer Therapeutics CRC top-up scholarship (S.G. and A.R.D.D.), and the operational infrastructure grants through the Australian Government IRIISS and the Victorian State Government OIS. S.G., A.R.D.D., B.J.A., C.J.V., and A.S. are employed by the Walter and Eliza Hall Institute, which receives milestone payments from Genentech and AbbVie for the development of ABT-199 for anti-cancer therapy.